Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Citado por Google
Similares en SciELO
Similares en Google
Compartir
Archivos de la Sociedad Española de Oftalmología
versión impresa ISSN 0365-6691
Resumen
AMSELEM, L. et al. Intravitreal injection of Bevacizumab (Avastin®) for retinal angiomatous proliferation. Arch Soc Esp Oftalmol [online]. 2008, vol.83, n.1, pp.53-55. ISSN 0365-6691.
Clinical case: An 81-year-old man presented with stage 2 retinal angiomatous proliferation (RAP) as identified by fluorescein angiography and optical coherence tomography (OCT), and was shown to have a visual acuity (VA) of 20/40. One week after an intravitreal injection of bevacizumab (1.25 mg) the VA improved to 20/25, and the OCT showed a reduction of both intraretinal edema and pigment epithelium detachment. Three months after the injection, no ocular complications were observed, VA was 20/20 and the OCT showed an almost normal macular contour. Discussion: Intravitreal injection of bevacizumab may provide another treatment option for patients with RAP.
Palabras clave : Bevacizumab; intravitreal injection; retinal angiomatous proliferation; age-related macular degeneration; optical coherence tomography.